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Abstract: Heat shock proteins (HSPs) are a deﬁ  ned set of chaperones for maintaining proper functions of proteins. The 
HSP70 family, one of the most inducible families in response to stress, protects cells from stress-induced cell death. It 
has been documented that HSP70s are highly expressed in various types of cancer cells and make the cells resistant to 
adverse microenvironments, such as hypoxia and glucose starvation, which are common features in malignant progression. 
Over-expression of HSP70s is thus associated with tumor transformation and eventually results in a decrease of 
chemotherapy efﬁ  cacy. Notably, the distribution of HSP70s is deregulated in cancer cells. It has been reported that 
HSP70s localize distinct organelles or are exported to humoral circulation during cancer development. Either surface 
or exported HSP70s play danger signals and trigger immune response to destroy the tumor cells. In this review, we lay 
out recent advances in the HSP70s-mediated cancer diagnosis and therapy. This review would be enlightening for 
clinical cancer medicine.
Introduction
In 1962, the chromosome puffs were observed in heat stressed Drosophila larvae and the encoded-genes 
were identiﬁ  ed as heat shock proteins (HSPs).
1,2 HSPs are also known to be mainly transactivated by 
heat shock factor to chaperone misfolded proteins and rescue cells from adverse environmental stresses, 
such as PH alteration, ischemia, hypoxia, osmotic and treatment with a number of metals.
3 According 
to molecular weight, HSPs are classiﬁ  ed into ﬁ  ve families including high molecular mass HSP100s, 
HSP90s, HSP70s, HSP60s and small HSPs.
3 Moreover, HSP100s function to disaggregate denatured 
proteins, while small HSPs inhibit aggregation of proteins.
4–6 HSP90s support the folding of premature 
proteins and play important signal transducers in cell differentiation and proliferation.
7 HSP70s coor-
dinate with HSP40s to fold nascent polypeptide chains,
8 while HSP60s, which is so-called chaperonin, 
and HSP10 are mostly responsible for folding mitochondrial proteins.
9 Among them, HSP70s is the 
most important HSPs for protein folding and is highly associated with tumor progression, which may 
also provide therapeutic strategy of cancer.
Human Heat Shock Protein 70 Family
In humans, the HSP70 family encompasses multiple distinct genes, which encode a group of highly 
related proteins: mitochondria resided glucose-regulated protein 75 (GRP75, HSPA9B locus) contains 
N-terminal mitochondrial localization signal, endoplasmic reticulum (ER) resided glucose-regulated 
protein 78 (GRP78, HSPA5 locus) contains N-terminal ER localization signal and C-terminal ER reten-
tion signal, cytosol/nuclear resided HSC70s (the cognate/constitutive HSP70, HSPA1L, HSPA2 and 
HSPA8 locus), and also cytosol/nuclear resided but highly inducible and intronless iHSP70s (HSP70/72; 
HSPA1A, HSPA1B, and HSPA6 loci) (Table 1).
10 Recent data indicates that some of HSP70s genes are 
signiﬁ  cantly induced in response to distinct stresses in humans. Two of these genes, HSPA1A and 
HSPA1B, are found as a nearly identical tandem pair in the major histocompatibility complex at 6p21.3 
region. HSPA1A and HSPA1B are coded for two almost identical proteins, the major inducible HSP70s 
in the stressed-cells.
11,12 Another inducible gene of HSP70s, HSPA6, is located on chromosome 1 and 
is mainly induced by extreme temperature.
13,14 However, the genes of HSC70s are ubiquitously expressed 
at low levels in most tissues, but show high expression level in speciﬁ  c tissues.
10,15–17 On the other hand, 
speciﬁ  c compartment-localized HSP70s, the genes HSPA5 and HSPA9 are not only constitutively 336
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expressed, but also induced under speciﬁ  c stress. 
HSPA5 is speciﬁ  cally induced in response to ER 
stress, while HSPA9 is induced by glucose 
starvation and ionizing radiation.
18–20 It indicates 
that HSP70s play crucial roles for cell survival 
under stresses. Additionally, HSP70s are upregu-
lated in a number of cancer cells, suggesting that 
HSP70s allow the cells to adapt to adverse 
microenvironments, such as hypoxia and glucose 
starvation, which are common features in tumor 
transformation.
Common Functions of HSP70s: 
Chaperone and Anti-apoptosis
HSP70s function as chaperones to control protein 
quality or interact with a number of key regulators 
to modulate cell proliferation, survival, and 
death.
21,22 The primary structure of HSP70s 
consists of around 45 kD ATPase domain and 
around 25 kD C-terminal peptide binding domain. 
The C-terminal domain can be further divided 
into two subdomains: peptide binding subdomain 
(15kD) and C-terminal subdomain (10 kD).
23 
While ATPase domain stimulates ATP hydrolysis 
to provide energy for protein folding, EEVD 
sequence of C-terminal subdomain recruits 
carboxyl terminus of HSC70-interacting protein 
with ubiquitin E3-ligase activity (CHIP) to trigger 
degradation of those malfolded proteins, which 
cannot be recovered.
24 HSP70s also associate with 
co-chaperones including HSP40s and nucleotide 
exchange factors to efﬁ  ciently stimulate protein 
folding. The chaperone activity of HSP70s is also 
required for blocking apoptosis caused by various 
stimuli, since deletion of ATPase domain or 
C-terminal EEVD sequence diminishes the anti-
apoptotic effect in response to stress.
25 However, 
while iHSP70s serve as safeguards to protect cells 
from apoptosis in a chaperone-dependent manner, 
iHSP70s interfere c-Jun N-terminal kinase (JNK) 
phosphorylation and abrogate JNK-mediated 
apoptosis in a chaperone independent manner 
(Fig. 1).
26
It has been found that the HSP70s prevent stress-
induced apoptosis through either mitochondria- 
dependent or independent pathways (Fig. 1). 
HSP70s can block activation of the death factors 
to allow the cells resistance to stress-induced apop-
tosis.
21 For instance, iHSP70s attenuate the release 
of cytochrome c by blocking cleavage of BH3-
interacting domain death agonist (Bid) from cas-
pase-8.
27 iHSP70s coupled with HSP40 prevent 
Bax mitochondrial translocation.
28 Moreover, 
iHSP70s interact with Apaf-1 to forbid its asso-
ciation with procaspase-9.
29 iHSP70s and HSP70-3 
also diminish cell death in caspase- independent 
pathway by inhibiting apoptosis inducing factor 
(AIF) and maintaining lysosomal membrane, 
respectively.
30,31 Furthermore, HSP70-3 siRNA 
induced p53 expression in HeLa cells, whereas 
siRNA of iHSP70s did not alter the p53 expression.
32 
Table 1. Classiﬁ  cation of human heat shock protein 70 family.
Protein Gene locus
symbol
Intracellular
localization
Alternative name PI/MW (kDa) Inducibility Reference
iHSP70s
HSP70-1 HSPA1A Nu/Cyto/Lyso HSP72, Hsp70, 
Hsp70i, Hsp70-1a
5.48/70.0 Yes 11, 12
HSP70-2 HSPA1B Nu/Cyto/Lyso HSP72, Hsp70, 
Hsp70-1b
5.48/70.0 Yes 11, 12
HSP70B’ HSPA6 Nu/Cyto Hsp7070-6 5.76/70.4 Yes 13, 14
HSC70s
HSC70 HSPA8 Nu/Cyto Hsp70-8, HSP73 5.81/71.0 No 15
HSP70-Hom HSPA1L Nu/Cyto Hsp70-1l, Hsp70t 5.48/70.0 No 16
HSP70-3 HSPA2 Nu/Cyto Hsp70-2, Hsp70-2b 5.07/72.3 No 17
GRP70s
GRP75 HSPA9 Mito Mortalin, mtHsp75, 
Hsp70-9, PBP74
5.37/70.9 Yes 19, 20
GRP78 HSPA5 ER Bip, Hsp70-5 6.03/73.7 Yes 18
Abbreviations: Nu: nucleus; Cyto: cytoplasm; Mito: mitochondria; ER: endoplasmic reticulum; PBP: peptide binding protein; Bip: Immunoglobulin 
heavy chain-binding protein homolog.337
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Also, PUMA, NOXA and Bcl2 antagonist of cell 
death (BAD) are critical mediators in apoptosis 
and transactivated by p53,
33,34 suggesting that 
HSP70-3 suppresses p53 expression to decrease 
stress-induced apoptosis.
On the other hand, overexpression of GRP78 
suppresses caspase-7/12 activation or stabilizes 
Raf-1 to maintain mitochondrial permeability, thus 
diminishing apoptosis in cells treated with ER 
stress inducers or genotoxic agents.
35–38 Recombinant 
GRP78 also reduces cytochrome c-induced 
caspase-3 activation in vitro.
39 Moreover, introduc-
tion of antisense GRP78 into cells decreases cell 
viability during ER stress stimuli.
40 Knockdown 
of GRP78 by siRNA arrests cell growth and 
increases activation of apoptosis regulator Bax or 
BCL2-interacting killer (BIK) in stress-induced 
apoptosis.
41,42 Besides, GRP75 interacts with p53 
in the cytoplasm to sequester its apoptotic 
function, thus reducing cell death caused by serum 
Figure 1. Protective mechanisms of HSP70s in stress-induced cell death. HSP70s block the activation of several death factors to 
attenuate stress-induced cell death. iHSP70s inhibit caspase-8, JNK, p53, AIF and apoptosome formation to protect cell from apoptosis. 
Moreover, both iHSP70s and HSC70s stabilize lysosomal membrane and decrease cathepsin-dependent cell death. Besides, GRP78 
diminishes caspase-dependent apoptosis by inhibiting Bax, BIK and caspase-7 activity. In addition, GRP75 traps p53 in the cytoplasm so 
that p53 cannot turn on the pro-apoptotic genes.338
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starvation.
43 Recent studies show that deregulation 
of HSP70s expression or functions is associated 
with diseases such as autoimmunity, neurodegen-
erative diseases, and tumor transformation, 
particularly in malignant progression.
3,44 It suggests 
that overexpression of HSP70s in tumor cells 
confers resistance to adverse microenvironments 
to promote tumor transformation and decrease 
chemotherapy efﬁ  cacy.
Involvement of HSP70s in Cancer
Overexpression of HSP70s is signiﬁ  cantly associ-
ated with tumor transformation since HSP70s may 
block apoptosis to adapt adverse microenviron-
ments as mentioned above or chaperone the 
mutated proteins of cancer cells, such as mutated 
p53, which is observed in approximately 50% 
cancers.
21,45 Moreover, the level of HSP70s is 
reportedly increased in a variety of tumor cells or 
tissues as followings (Table 2).
iHSP70s
Several reports have shown that increased iHsp70s 
expression is elevated in a variety of malignant 
tumors, such as colorectal, esophageal and gastric 
cancer.
46–48 The expression level of HSP70-1 and/
or -2 is elicited in either pancreatic cancer cells
49 
or melanoma cell lines.
50 The importance of these 
ﬁ  ndings is illustrated by the fact that high levels 
of expression of HSP70-1 and/or HSP70-2 are 
correlated with hepatoma progression
51 and 
increased drug resistance of human breast can-
cer.
52,53 Overexpression of HSP70-1 and/or 
HSP70-2 expands the tumor size, metastasis and 
resistance to chemotherapy.
54 The polymorphism 
of HSP70-2 is associated with nasopharyngeal 
Table 2. Association of HSP70s in cancers.
Protein Findings Cancer type Reference
iHSP70s HSP70-1 and/or -2 expression 
are increased in the cancer
Breast cancer 52
Colon cancer 48
Gastric cancer 46
Melanoma 50
Tumorigenic cells (HeLa,
MCF-7, PC-3, HuH-7, SGC-7901)
32, 59
HSP70-2 polymorphism associ-
ates with the cancer
Nasopharynx cancer 55
HSP70-1 and/or -2 decrease 
chemotherapy efﬁ  ciency
Bladder cancer (BIU-87) 58
HSC70s HSP70-3 expression is increased 
in the cancer and reduce cell 
death
Bladder cancer 31
HSP70-3 regulates cell prolifera-
tion
Cervix cancer (HeLa) 32
GRP75 GRP75 expression is elevated in 
the cancer
Brain cancer 62
Breast cancer 63
Colon cancer 63
Elevated GRP75 in cancer cells 
decreases survival of the patient
Colon cancer 64
GRP78 GRP78 expression is increased in 
the cancer
Liver cancer 75
Lung cancer 72
Colon cancer 70
Gastric cancer 68, 71
GRP78 shortens the time 
of recurrence
Breast cancer 66339
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carcinoma
55 and increases the viability of patients 
with breast cancer.
56 Speciﬁ  cally, the cytoplasmic 
HSP70-1 and/or -2 are more abundant in the 
colorectal carcinoma than in the normal mucosa.
57 
Also, depletion of the genes HSPA1A and/or 
HSPA1B by antisense nucleotides in human blad-
der cancer cell lines BIU-87 sensitizes mitomycin 
C-based chemotherapy.
58 Knockdown of the genes 
HSPA1A and/or HSPA1B by siRNA arrests cell 
cycle at G2/M phase to diminish cell proliferation 
of tumorigenic cells including HeLa, MCF-7, PC-3, 
HuH-7 and gastric cancer SGC-7901 cells, whereas 
the effect is not observed in nontumorigenic 
HBL-100 cells.
32,59 However, siRNA of the gene 
HSPA6 reveals no effect in both HeLa and 
HBL-100 cells.
32
HSC70s
Compared with peripheral blood mononuclear 
cells (PBMC), HSC70 shows high levels of 
expression in the epithelial cancer cells including 
oral cancer (OSC20 and Ca9-22), colon cancer 
(SW620) and stomach cancer (MKN45).
60 The 
gene HSPA2 is elevated in invasive bladder cancer 
and tissue from patients with breast cancer.
31,32 
Nevertheless, HSPA1L shows no correlation with 
prostate cancer risk.
61
GRP75
GRP75 shows induced-expression in many types 
of brain tumors including meningiomas, neurino-
mas, pituitary adenomas and metastases.
62 The 
mRNA level of GRP75 is upraised in tumor tissues 
of breast, brain, and colon tumors in the mouse 
model.
63 The gene HSPA9 expression in most of 
tumor or immortalized cell is higher than that in 
normal cells.
63 Malignancy of breast cancer is 
enhanced in GRP75-overexpressed cells.
63 Besides, 
elevated expression of GRP75 decreases survival 
of the patient with colon cancer.
64
GRP78
The microenvironment in tumor transformation 
induces ER stress response to stimulate GRP78 
expression. The mRNA and protein level of GRP78 
in the tumor tissue are much higher than that in the 
normal tissue of patients with lung cancer, indicat-
ing that the level of GRP78 greatly correlates with 
malignant progression.
65 Besides, the expression 
level of GRP78 is signiﬁ  cantly associated with a 
shorter time of recurrence in patients with breast 
cancer.
66 The elevated protein level of GRP78 is 
also observed in resected tissue from patients with 
a number of cancer types including liver, lung, 
prostate, colon, and gastric cancer,
67–71 whereas 
the mRNA level had no difference in colon cancer, 
suggesting that posttranscriptional regulation may 
be involved in the GRP78 expression.
72 A recent 
report shows that GRP78 inhibits BIK, a BH3-only 
proapoptotic protein in ER, or molecularly chap-
erone Raf-1 to diminish stress-induced apoptosis 
in human breast cancer MCF-7/BUS cells or non-
small cell lung cancer H460 cells.
38,73 Therefore, 
it indicates that GRP78 could be a treatment marker 
in chemotherapy.
Heat shock factor 1 (HSF1) and activating 
transcription factor 6 (ATF6), the transcription 
factors of iHSP70s and GRP78, respectively, are 
overexpressed in some certain cancer cells.
74,75 
This is probably why the expression level of 
HSP70s is elevated in tumor cells. Additionally, 
since the anti-apoptotic and chaperone functions 
of HSP70s promote tumor transformation, the 
induction of HSP70s play pivotal roles in 
carcinogenesis.
66,76 It may also provide diagnostic 
markers of cancer.
Distribution of HSP70s in Cancer
Besides the high level expression of HSP70s in 
tumor cells, HSP70s have also been observed to 
distribute distinct subcellular localization.
77–79 
HSP70s associate with either tumor-speciﬁ  c anti-
gen to localize on the surface or proapoptotic 
protein to inhibit its function, which may provide 
a pharmacological strategy in cancer therapy.
iHSP70s
In addition to nucleus/cytoplasm localization, the 
minority of HSP70-1 and/or HSP70-2 associated 
with tumor speciﬁ  c antigens localizes on the cell 
surface and serves as a danger signal to trigger an 
immune response in patients with cancer.
80 Cell 
surface-localized HSP70-1, HSP70-2 or its derived 
peptide TKDNNLLGRFELSG (TKD, aa 450–463) 
interact with CD94 of natural killer (NK) cells to 
trigger the granzyme B released from NK cells.
81 
The released granzyme B is internalized into tumor 
cells by interacting with surface-localized HSP70-1 
and/or HSP70-2 and initiates apoptosis in a 
perforin-independent manner.
81 However, distinct 
length of TKD-related peptides or TKD-equivalent 340
Shu and Huang
Clinical Medicine: Oncology 2008:2 
peptides derived from HSP70-Hom or HSC70 
cannot activate NK cells.
82 Moreover, HSP70-1 
and/or HSP70-2 stimulate pro-inflammatory 
cytokines secretion of antigen presenting cells 
(APC)s through binding with Toll-like receptors.
83 
Interestingly, HSP70-1 and/or HSP70-2 also exist 
at high levels in the sera of prostate cancer 
patients.
84
HSC70s
HSC70 has been found on the cell surface as 
HSP70-1 and/or HSP70-2 and is released to 
extracellular space in the K562 erythroleukemic 
cells treated with pro-inflammatory cytokine 
interferon-gamma (IFN-γ).
78 Likewise, HSC70 
co-localizes with tumor antigens and MHC class 
I molecules in the exosome released from 2 
different types of MHC-mouse cell lines including 
CT26 (H-2d MHC) and TA3HA (H-2a MHC).
85 
The HSC70-contained exosomes activate dendritic 
cells and suppress tumor size in the colon 
cancer-bearing mice.
85
GRP75
GRP75 localizes in duplicated centrosome at late 
G1, S, and G2 phases of the cell cycle, whereas it 
dissociates with unduplicated centrosome at M 
phase.
86 GRP75 is tyrosine phosphorylated at G1 
phase in the cells exposed to ﬁ  broblast growth 
factor (FGF) and correlated with FGF-1 induced 
cell growth.
87 Moreover, GRP75 interacts with 
mot-2-binding site (aa 323–337) of p53 to trap p53 
in the cytoplasm and inhibit its apoptotic func-
tion.
88
GRP78
GRP78 is observed in the other sub-cellular 
compartments except ER. Surface-localized 
GRP78 is increased in LNCaP prostate cancer 
cells treated with synthetic androgen R1881.
79 
The peptide sequence LIGRTWNDPSVQQDIKFL 
(aa 98-115) of surface-localized GRP78 binds 
to receptor binding domain (RBD) of α2-
macroglobulin (α2M*) and serves as a receptor 
of α2M* to promote cell growth via PI3K/AKT 
dependent pathway.
89,90 Moreover, GRP78 
accumulates in the cytoplasm in hepatocellular 
carcinoma (HCC).
75 Besides, recent study shows 
that autoantibody against GRP78 is increased in 
sera of the patients with prostate cancer.
90 Further, 
the antibody isolated from the patients enhances 
the proliferation of 1-LN cells expressing GRP78 
on the cell surface.
90 The anti-GRP78 antibody 
also prevents apoptosis in cells exposed to tumor 
necrosis factor α
90.
In addition to distinct intracellular distribution 
of HSP70s, HSP70s are exported to serum in 
cancer patients.
91,92 Also, anti-HSP70s antibodies 
have been determined in some certain cancers.
84,90 
Although the function of HSP70s release or 
autoantibody production needs more studies to 
examine, it implies that they can be treated as 
diagnostic or prognostic markers in cancer 
therapy.
HSP70s in Cancer Therapy
Since overexpression and dysregulation of HSP70s 
are involved in tumor transformation, HSP70s play 
the role of danger signals in patients with cancer. 
According to the features of HSP70s in cancer, 
HSP70s—based cancer therapy has been veriﬁ  ed 
in some certain cancers (Table 3).
iHSP70s
Ex vivo activation of NK cells from patients with 
metastasized colon and lung cancer by IL-2/TKD 
peptide treatment has been tested for its tolerabil-
ity, feasibility, and safety in phase I clinical trial.
93 
The activated NK cells show cytolytic activity to 
surface HSP70 (HSP70-1 and/or HSP70-2) posi-
tive tumor cells in vivo and most patients experi-
enced no negative side effects. Furthermore, the 
IL-2/TKD peptide- activated NK cells, but not 
T lymphocyte, which decreased the tumor weight 
and liver metastasis, thereby increasing the survival 
rate of pancreatic tumor-bearing mice.
94 Introduc-
tion of antisense cDNA against HSPA1A and/or 
HSPA1B to nude mice efﬁ  ciently diminishes the 
tumor growth of glioblastoma, breast and colon 
cancer.
53 Depletion of HSPA1A and/or HSPA1B 
by siRNA or HSP70s by quercetin, which is an 
inhibitor of HSF1,
95 raises the apoptosis of human 
pancreatic cancer cells including MiaPaCa-2 and 
Panc-1 in a caspase-dependent manner.
49 Also, 
injection of quercetin into the mouse xenografted 
with MiaPaCa-2 tumor cells signiﬁ  cantly attenuates 
the tumor size.
49 Likewise, triptolide derived from 
Triptergium wilfordii blocks HSF1 transcriptional 
activity without affecting its activation and DNA 
binding activity, thus diminishing the genes 
HSPA1A and/or HSPA1B expression and enhances 341
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stress-induced apoptosis.
96 Moreover, cardenolide 
(UNBS1450), a potent anti-cancer drug for the 
paclitaxel-and oxaliplatin-resistant tumor, attenu-
ates both mRNA and protein levels of HSP70-1 
and/or HSP70-2 in human non-small cell lung 
cancers partly through suppression of NFAT5/
TonEBP, which regulates transcriptional levels of 
iHSP70s.
97 It supports the notion that induction of 
iHSP70s associates with not only malignant pro-
gression, but also drug resistance. However, since 
HSF1 transactivates most of inducible HSPs genes, 
inhibiting HSF1 not only block iHSP70s expres-
sion, but other inducible HSPs, which may appear 
side effect in the treatment.
HSC70s
Like HSP70-1 and/or HSP70-2, extracellular 
HSC70 has been determined to function as a cyto-
kine to activate an immune response leading to 
tumor suppression.
78 HSC70-derived peptide 
EYKGETKSF (aa 106–114) or FDNRMVNHF (aa 
233–241) activate cytotoxic T lymphocyte (CTL) 
in the peripheral blood mononuclear cells of epi-
thelial cancer patients.
60 Besides, inhibiting 
the gene HSPA8 expression by siRNA shows 
anti-proliferative effects in both tumorigenic and 
non-tumorigenic cells.
32 Nevertheless, HSP70-3 
depletion arrests the cell cycle at G1 phase of HeLa 
cells, whereas the effect is not observed in normal 
cells. Depletion of the gene HSPA2 induces expres-
sion of macrophage inhibitory cytokine-1, a target 
of p53, in both p53 dependent and independent 
pathways to arrest cell cycle at G1 phase.
32 Sup-
pression of the gene HSPA2 expression also results 
in cathepsin-dependent cell death via permeabiliz-
ing the lysosomal membrane.
31
GRP75
Several studies have shown the importance of the 
interaction between GRP75 and p53 in carcino-
genesis.
43,88 Therefore, suppression of the gene 
HSPA9 expression or interference with interaction 
would be a therapeutic strategy against cancer. 
Indeed, knockdown of the gene HSPA9 by 
ribozyme or siRNA reduces cell growth and viabil-
ity of human cancer cells.
98,99 Disrupting the 
interaction between GRP75 and p53 by the potent 
anti-cancer drug, MKT-077,
100 or GRP75 binding 
Table 3. Potential HSP70s-based cancer therapy.
Protein Mechanism of action Therapy Reference
iHSP70s Activate NK cells against cancer  IL-2/TKD peptide 93
cells with surface iHSP70s (immunotherapy) 94
Inhibit iHSP70s expression Antisense iHSP70s cDNA 53
siRNA 49
Quercetin 49
Cardenolide (UNBS1450) 97
Triptolide 96
HSC70s Activate CTL HSC70-derived peptide 
(immunotherapy)
78
Inhibit HSC70s expression siRNA 32
GRP75 Inhibit GRP75 expression ribozyme 98
siRNA 99
Disrupt interaction between 
GRP75 and p53
MKT-077 100
GRP75 binding peptide 88
GRP78 Inhibit gene expression siRNA 71, 101
The binding peptide conjugated 
with cytotoxic peptide kill the 
cancer cells with surface 
localized-GRP78
GRP78 binding peptides 105, 106
Cleave GRP78 at Leu 416 SubAB 104
Block GRP78 in the ER MDA-7/IL-24 recombinant 
adenoviruses
102342
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peptide, activates endogenous p53, thus preventing 
cell growth of osteosarcoma and breast carcinoma 
cells.
88
GRP78
Since GRP78 associates with tumor transformation 
and cancer therapy, it provides a good therapeutic 
target for several potent anti-cancer drugs. For 
instance, suppression of HSPA5 by siRNA 
increases sensitivity of tumor cells to etoposide in 
mice xenografted with human breast cancer.
101 
Moreover, Melanoma differentiation-associated 
gene-7/interleukin-24 (MDA-7/IL-24) and its 
derived peptide M4 interact with GRP78 in ER 
lumen to trigger ER stress response, which in turn 
promotes apoptosis of cancer cells.
102 Injection of 
MDA-7/IL-24 recombinant adenoviruses (Ad. 
Mda-7) into breast tumor-bearing mice results in 
a decrease of tumor volume.
102 In phase I clinical 
trial of Ad. Mda-7 in patients with melanoma, it 
has been determined to be safe and efﬁ  cient in 
inducing apoptosis of melanoma.
103 Additionally, 
SubAB, a toxin from the highly virulent strain of 
Escherichia coli, cleaves GRP78 at Leu 416 site 
to destroy its function, which may provide a 
therapeutic application.
104 On the other hand, 
surface-localized GRP78 could be utilized as a 
carrier of anti-cancer drugs. The cyclic 13-mer 
oligopeptide, Pep42, interacts with surface-
localized GRP78 and internalizes to lysosome of 
tumor cells in a clathrin-dependent manner.
105 
Pep42 also targets tumor tissue in the xenograft 
mice with melanoma cells. Furthermore, Pep42 
conjugated with the apoptosis-inducing oligopeptide 
(AIO) or photosensitizer decreases viability of 
tumor cells, such as A549 and HepG2 cells; 
whereas the effect is not observed in normal 
cells.
105 Likewise, the GRP78 binding peptides, 
WIFPWIQL or WDLAWMFRLPVG, fused with 
AIO decreases the tumor size in the xenograft mice 
with prostate and breast cancers.
106
While some of the surface-localized HSP70s 
(HSP70-1, HSP70-2, and HSC70) serve as danger 
signals in cancer patients, surface-localized GRP78 
serves as a receptor of α2M* to promote cancer 
cell growth. Inhibiting HSP70s genes expression 
by siRNA or inhibitors might also diminish the 
danger signal from the surface-localized HSP70. 
Therefore, HSP70s-based cancer therapy may 
depend on the speciﬁ  city of induced or surface-
localized HSP70s in the patient.
Conclusion and Perspective
While HSP70s play pivotal roles for general 
peptide folding to maintain normal physiological 
function of cells, dysregulation of expressional 
and spatial control of HSP70s causes tumor 
transformation and decreases chemotherapy 
efﬁ  cacy. Therefore, comprehension of molecular 
mechanisms regarding gene regulation and pro-
tein function of HSP70s might provide a paradigm 
for cancer therapy. Although plenty of studies 
about HSP70s-based cancer therapy have been 
determined, most of the studies are still in cell or 
preclinical models. The efﬁ  cacy of HSP70s-based 
cancer therapy needs to be further veriﬁ  ed in the 
clinical trial. On the other hand, since overexpressed 
HSP70s demonstrate variable localization as 
mentioned above and some of HSP70s reveal 
posttranslational modiﬁ  cation in tumor cells,
107 
the relevance between post-translational modiﬁ  -
cation and distribution of HSP70s remains 
unclear. To determine the detailed mechanism of 
HSP70s in tumor progression, HSP70s-based 
chaperosome using a proteomics approach would 
be informative in the regulation of HSP70s in 
cancers, which in turn would shed light on the 
cancer therapy.
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